摘要
目的 探讨川芎嗪联合氨基胍对糖尿病视网膜病变防治作用及其机制。方法 用链尿佐菌素 (STZ)制作糖尿病大鼠动物模型 ,分为正常对照组、糖尿病对照组、糖尿病氨基胍治疗组、糖尿病川芎嗪 +氨基胍治疗组 ,于第 12周测定大鼠视网膜组织NO的含量、NOS活性和AR的活性。结果 糖尿病川芎嗪 +氨基胍治疗组、糖尿病氨基胍治疗组大鼠视网膜组织NOS及AR活性显著低于糖尿病对照组 (P <0 0 1) ,NO的含量升高 (P <0 0 1) ;糖尿病氨基胍治疗组仍高于正常对照组 (P <0 0 1) ,NO的含量降低 (P <0 0 1) ;糖尿病川芎嗪 +氨基胍治疗组与正常组无显著差异。结论 川芎嗪联合氨基胍能够抑制糖尿病大鼠视网膜组织NOS、AR活性 。
ObjectiveTo investigate the protective effect of Tetramethylprazine (TMP)combined aminoguanidine(AG) on diabetic retinopathy.MethodsFifty SD rats were divided randomly into 4 groups.At the 12 th experimental week,the activities of nitric oxide synthase (NOS) and aldose reductase (AR) in retinal tissue were determined in control group (C group)and streptozotocin induced diabetic rats,which were divided into diabetes control group(DM group),Aminoguanidine treated group(AG group) and TMP combined AG treated group (T+AG group).ResultsAfter 12 weeks,the activities of NOS and AR in retina of TMP+AG group were reduced in comparison with the DM group and AG group. ConclusionTMP combined AG can prevent the development of diabetic retinopathy partly by restraining the activities of retinal NOS and AR.
出处
《眼科研究》
CAS
CSCD
北大核心
2003年第2期133-135,共3页
Chinese Ophthalmic Research
基金
福建省自然科学基金资助 (C981 0 0 34)
关键词
川芎嗪
氨基胍
糖尿病视网膜病变
醛糖还原酶
一氧化氮合酶
Tetramethylprazine Aminoguanidine diabetic retinopathy aldose reductase nitric oxide synthase
